Being a co-founder of Immatics, Toni leads the discovery and validation of novel and innovative I/O targets. Furthermore, he is responsible for advancing Immatics' vision for ultra-personalized multi-target immunotherapies and the XPRESIDENT®-AI data computing platform and leads the development of companion diagnostics (CDx) for Immatics' product candidates. Toni is member of the Operational Site Team in Tübingen.
Over the past two decades, Toni Weinschenk has been active in the field of cancer immunology. He oversees all of Immatics’ target discovery and companion diagnostics activities.
He is the inventor of Immatics’ proprietary XPRESIDENT® technology platform, which is enabling the discovery and validation of the most comprehensive array of cancer targets derived from both, cell surface and intracellular antigens. Toni Weinschenk has earned the reputation as one of the world’s leading expert in ultra-sensitive, quantitative and high-throughput mass spectrometry of HLA ligands, a technology that is integral to XPRESIDENT®. Targets identified by XPRESIDENT® have proven to be important assets in several licensing deals with partners from the pharma industry and academia.
Toni Weinschenk is an inventor on many patents and co-authored publications in the cancer immunology field in prestigious peer-reviewed journals including Nature, Nature Medicine, Nature Immunology, Immunological Reviews and Cell Report.
Toni Weinschenk studied biochemistry at the University of Tuebingen, Germany.